 | ||
 | | |
 | ||
 | ||
 | | |
| | |
|
 |
|
|
||
 |
||
|
||
| Les informations publiées par la revue Prescrire
présentent un intérêt bien au delà des
limites de la francophonie. C’est pourquoi l’Association
Mieux Prescrire a décidé de publier régulièrement,
depuis 1992, des sélections de textes de la revue Prescrire
en anglais, langue la plus utilisée aujourd’hui par la
communauté médicale et pharmaceutique mondiale. Prescrire International regroupe, tous les deux mois, une sélection de textes de la revue Prescrire, minutieusement traduits en anglais par des professionnels anglophones, sous le contrôle de la Rédaction de la revue Prescrire. L’abonnement d’un an à Prescrire International comprend la livraison de 6 numéros de 40 pages et d’un index détaillé couvrant les 5 dernières années. Les abonnés à Prescrire International, répartis dans près de 70 pays, sont parfois des praticiens de terrain, mais le plus souvent des "personnes relais" (universitaires, responsables d’associations de formation, de centres de documentation, d’agences administratives ou d’évaluation du médicament, etc.). |
 |
|
|
||
|
||
| Prescrire International is the concise, English language version of la revue Prescrire. Prescrire International is a unique source of independent comparative information on drugs and other therapeutic interventions. The New Drugs section provides you with comparative assessments of new drugs and news indications. The Reviews section gives you assessments of therapeutic interventions as well as treatment guidelines that will help you to offer your patients effective care based on the best availabe evidence. The Adverse Effects section gives you a balanced view of the latest suspected or confirmed adverse drug reaction data collected from the many published and unpublished data sources all over the world. |  |
|
|
||
|
||
| Prescrire International n°96, August 2008 | ||
|
||
| Editorial The constant practitioner Resist the urge to overmedicate (p.134) |
||
|
||
| New Products Raltegravir (in multidrug-resistant HIV) Alternative to enfuvirtide/darunavir (p.135) |
||
|
||
| Adalimumab (severe Crohn's disease) A second TNF alpha antagonist (p.137) |
||
|
||
| Metformin (dispersible tablets) A welcome formulation (p.138) |
||
|
||
| Solostar° pen for glargine and glulisine insulins Less convenient than Innolet° pen (p.138) |
||
|
||
| Inhaled insulin no longer marketed Welcome news (p.139) |
||
|
||
| Inhaled insulin and lung cancer (p.139) | ||
|
||
| Kaletra° oral solution Modification of confusing label (p.140) |
||
|
||
| Zanamivir (in children over 5 years) Influenza in children and adults: symptom relief or vaccination (p.141) |
||
|
||
| Common stems - INN -tegravir (p.141) |
||
|
||
| Daily tadalafil Beware medicalisation of human existence (p.142) |
||
|
||
| Zoledronic acid (postmenopausal osteoporosis) No therapeutic advantage (p.143) |
||
|
||
| Betamethasone plaster Just a useless gadget (p.144) |
||
|
||
| Infliximab (severe Crohn's disease in children) Many unknowns (p.145) |
||
|
||
| Fentanyl by iontophoresis (postoperative analgesia) A step backwards compared with intravenous morphine (p.146) |
||
|
||
| Shortcuts. Dasatinib - carbetocin - rufinamide (p.149) | ||
|
||
| Adverse Effects Colchicine: serious interactions (p.151) |
||
|
||
| Death due to intrathecal vindesine (p.153) | ||
|
||
| Isotretinoin and intestinal damage (p.154) | ||
|
||
| SSRI antidepressants and persistent pulmonary hypertension in newborns (p. 156) | ||
|
||
| Iatrogenic burns: beware of microwaves! (p.157) | ||
|
||
| Atrial-oesophageal fistula after radiofrequency ablation (p.158) | ||
|
||
| Cancer chemotherapy: sometimes takes the pleasure out of eating (p.159) | ||
|
||
| Clozapine: ileus (p.160) | ||
|
||
| HPV 6, 11, 16, 18 vaccine: pharmacovigilance reports in 2007 (p.160) | ||
|
||
| Benzalkonium chloride: death of an asthmatic patient (p.160) | ||
|
||
| Bisphophonates and atrial fibrillation (p.161) | ||
|
||
| Cysteamine: Ehlers-Danlos syndrome (p.161) | ||
|
||
| Confusion and stroke due to an "umbrella brand" product (p.161) | ||
|
||
| Reviews Artemisinin derivatives and malaria Prescrire's advice: Treatment of uncomplicated malaria attacks (p.162) |
||
|
||
| Intravenous artesunate for severe malaria An alternative to intravenous quinine ( p.168) |
||
|
||
| Treatment of facial lipoatrophy in HIV-infected patients
Switching drugs, surgery or polylactic acid (p.170) |
||
|
||
| Outlook Editorial Distinguishing between research and clinical care (p.171) |
||
|
||
| Access Artemisinin in Africa (p.172) |
||
|
||
| Prevention Waterpipe smoking: risky, but increasingly popular (p.173) |
||
|
||
| Forum The Advance trial and type 2 diabetes (continued) (p.173) |
||
|
||
|
||
|
|
|
